Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

Brief description of study

Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors


Clinical Study Identifier: s23-00360
ClinicalTrials.gov Identifier: NCT05732831
Principal Investigator: Salman Rafi Punekar.
Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Samantha VanMaanen, Douglas K Marks, Jessica Wang, Elaine Shum, Nina Beri, Kristen Spencer, Scot Niglio, Keriann M Scavone, Kathleen M Madden, Nancy Chan, Caitlin Elizabeth Ryan, Eneil De La Pena, Janice Mehnert, Vamsidhar Velcheti.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.